Применение метаболомного подхода для идентификации непептидных молекул с дифференцированной экспрессией при артериальной гипертензии беременных

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005; 365(9461): 785-99.
2. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am. J. Obstet. Gynecol 2000; 183(1): S1-S22.
3. Dekker G., Sibai B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet. 2001; 357(9251): 209-15.
4. Huang L.Y., Lu W.L., Sun Z. Risk factors of pregnancy-induced hypertention syndrome: A meta-analysis. Chin. Prev. Med. 2012; 13(3): 225-7.
5. Maxiang L., Xiaoxian L. A case-control study on risk factors of pregnancy--induced hypertension syndrome. Chin. J. Soc. Med. 2009; 26: 177-9.
6. Junxia X., Jinghui R., Xiaoxian L. Stepwise logistic regression analysis on high risk factors about pregnancy-induced hypertension (PIH) syndrome. Chin. Matern. Child Health Care. 2006; 16: 2209-10.
7. Mustafa R., Ahmed S., Gupta A., Venuto R.C. A comprehensive review of hypertension in pregnancy. J Pregnancy. 2012; 2012: 105918.
8. Charnock-Jones D.S., Kaufmann P., Mayhew T.M. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta. 2004; 25(2-3): 103-13.
9. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of pre-eclampsia. N. Engl. J. Med. 2004; 350(7): 672-83.
10. Knudsen U.B., Kronborg C.S., von Dadelszen P., Kupfer K., Lee S.W., Vittinghus E. et al. A single rapid point of care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens. 2012;2(1): 8-15.
11. Ohkuchi A., Hirashima C., Matsubara S., Takahashi K., Matsuda Y., Suzuki M. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension. 2011; 58(5): 859-66.
12. Kim S.Y., Ryu H.M., Yang J.H., Kim M.Y., Han J.Y., Kim J.O. et al. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J. Korean Med. Sci. 2007; 22(5): 873-7.
13. Molvarec A., Szarka A., Walentin S., Szucs E., Nagy B., Rigó J. Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters n women with pre-eclampsia. Hypertens. Res. 2010; 33(9): 892-8.
14. Powers R.W., Jeyabalan A., Clifton R.G., Van Dorsten P., Hauth J.C., Klebanoff M.A. et al. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and lacental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010; 5(10): e13263.
15. Nadarajah V.D., Min R.G., Judson J.P., Jegasothy R., Ling E.H. Maternal plasma soluble fms-like tyrosine kinase-1 and placental growth factor levels as biochemical markers of gestational hypertension for Malaysian mothers. J. Obstet. Gynaecol. Res. 2009; 35(5): 855-63.
16. Khalil A., Muttukrishna S., Harrington K., Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One. 2008; 3(7): e2766.
17. Chaiworapongsa T., Romero R., Korzeniewski S.J., Kusanovic J.P., Soto E., Lam J. et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am. J. Obstet. Gynecol. 2013; 208(4): 287.e1-287. e15.
18. Kalkunte S., Nevers T., Norris W.E., Sharma S. Vascular IL-10: a protective role in preeclampsia. J. Reprod. Immunol. 2011; 88(2): 165-9.
19. Lai Z., Kalkunte S., Sharma S. A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice. Hypertension. 2011; 57(3): 505-14.
20. Zhou P., Luo X., Qi H.B., Zong W.J., Zhang H., Liu D.D., Li Q.S. The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm. Res. 2012; 61(9): 1005-12.
21. Saito S., Umekage H., Sakamoto Y., Sakai M., Tanebe K., Sasaki Y., Morikawa H. Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. Am. J. Reprod. Immunol. 1999; 41(5): 297-306.
22. Gupta S., Agarwal A., Sharma R.K. The role of placental oxidative stress and lipid peroxidation in preeclampsia. Obstet. Gynecol. Surv. 2005;60(12): 807-16.
23. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of anti-angiogenic factors and implications for later cardiovascular disease. Circulation. 2011; 123(24): 2856-69.
24. de Jager C.A., Shephard E.G., Robson S.C., Jaskiewicz K., Froese S. , Anthony J., Kirsch R.E. Degradation of fibronectin in association with vascular endothelial disruption in preeclampsia. J. Lab. Clin. Med. 1995; 125(4): 522-30.
25. Struck J., Morgenthaler N.G., Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides. 2005; 26(12): 2482-6.
26. Fiore G., Florio P., Micheli L., Nencini C., Rossi M., Cerretani D. et al. Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia. J. Clin. Endocrinol. Metab. 2005; 90(7): 4205-10.
27. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995; 377(6546): 239-42.
28. Zhou R., Li W., Cao Z. The changes and significance of the intensity of transcription of endothelial nitric oxide synthase-mRNA in placental tissue from cases of pregnancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi. 1998; 33(12): 709-10.
29. Gu Y., Lewis D.F., Zhang Y., Groome L.J., Wang Y. Increased superoxide generation and decreased stress protein Hsp90 expression in human umbilical cord vein endothelial cells (HUVECs) from pregnancies complicated by preeclampsia. Hypertens. Pregnancy. 2006; 25(3): 169-82.
30. Steinert J.R., Wyatt A.W., Poston L., Jacob R., Mann G.E. Preeclampsia is associated with altered Ca2+ regulation and NO production in human fetal venous endothelial cells. FASEB J. 2002; 16(7): 721-3.
31. Orange S.J., Painter D., Horvath J., Yu B., Trent R., Hennessy A. Placental endothelial nitric oxide synthase localization and expression in normal human pregnancy and pre-eclampsia. Clin. Exp. Pharmacol. Physiol. 2003; 30(5-6): 376-81.
32. Schiessl B., Mylonas I., Hantschmann P., Kuhn C., Schulze S., Kunze S. et al. Expression of endothelial NO synthase, nducible NO synthase, and estrogen receptors alpha and beta in placental tissue of normal, preeclamptic, and intrauterine growth-restricted pregnancies. J. Histochem. Cytochem. 2005; 53(12): 1441-9.
33. Rytlewski K., Olszanecki R., Lauterbach R., Grzyb A., Basta A. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report. Basic Clin. Pharmacol. Toxicol. 2006; 99(2): 146-52.
34. Smith C.A., O’Maille G., Want E.J., Qin C., Trauger S.A., Brandon T.R. et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 2005; 27(6): 747-51.
35. Dunn W., Ellis D. Metabolomics: current analytical platforms and methodologies. Trends Anal Chem. 2005; 24(4): 285-94.
36. Tomita M., Nishioka T., eds. Metabolomics: the frontier of systems biology. Springer; 2005.
37. Mamas M., Dunn W.B., Neyses L., Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch. Toxicol. 2011; 85(1): 5-17.
38. Kenny L., Dunn W., Ellis D., Myers J., Baker P., Consortium G., Kell D. Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics. 2005; 1(3): 227-34.
39. Xuemei Lou, Chenhong W., Dayan L. Plasma metabonomics in severe pre-eclampsia. J. Pract. Obstet. Gynecol. 2011; 27(12): 928-32.
40. Fu M., Li Z., Tan T., Guo W., Xie N., Liu Q. et al. Akt/eNOS signaling pathway mediates inhibition of endothelial progenitor cells by palmitate-induced ceramide. Am. J. Physiol. Heart Circ. Physiol, 2015; 308(1): H11-7.
41. Wang A., Li C., Liao J., Dong M., Xiao Z., Lei M. Ceramide mediates inhibition of the Akt/eNOS pathway by high levels of glucose in human vascular endothelial cells. J. Pediatr. Endocrinol. Metab. 2013; 26(1-2): 31-8.
42. Ren H., Zhang C., Su L., Bi X., Wang C., Wang L., Wu B. Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway. Biochem. Biophys. Res. Commun, 2015; 457(4): 572-7.
43. Wang M., Yu T., Zhu C., Sun H., Qiu Y., Zhu X., Li J. Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr. Cancer, 2014; 66(3): 435-40.
44. Srivastava A., Gupta P.K., Knock G.A., Aaronson P.I., Mishra S.K., Prakash V.R. Effect of ceramide on the contractility of pregnant rat uterus. Eur. J. Pharmacol. 2007; 567(1-2): 159-65.
45. Kitos T.E., Choi C.M., Cornell R.B. Angiotensin stimulates phosphatidylcholine synthesis via a pathway involving diacylglycerol, protein kinase C, ERK1/2, and CTP: phosphocholine cytidylyltransferase. Biochim. Biophys. Acta. 2006; 1761(2): 272-9.
46. Parchim N.F., Wang W., Iriyama T., Ashimi O.A., Siddiqui A.H., Blackwell S. et al. Neurokinin 3 receptor and phosphocholine transferase: missing factors for pathogenesis of C-reactive protein in preeclampsia. Hypertension. 2015; 65(2): 430-9.

Поступила 19.12.2018

Принята в печать 22.02.2019